Spark Therapeutics stock price target raised to $80 from $51 at UBS

1 BUSINESS

Business News - Opportunities - Reviews

 

 

Spark Therapeutics loss widens

Spark Therapeutics Inc. ONCE on Tuesday reported a widened 2017 net loss, after booking an R&D impairment charge, as well as higher costs. The Philadelphia-based gene therapy company posted a loss of $253.5 million, or $7.63 a diluted share, compared with a loss of $123.7 million, or $4.29, for the same period the year before.

1 BUSINESS

Business News - Opportunities - Reviews

 

 

Leave a Reply